Martin P, Dubois, et al. Gut. 2014 Nov 26, doi: 10.1136/gutjnl-2014-308041 – Download the article Publication
Category: 2014
TG4010 Immunotherapy Combined with First-line Therapy in Advanced Non- Small Cell Lung Cancer (NSCLC). Phase 2b Results of the TIME Study
Elisabeth Quoix, et al. Journal for Immunotherapy of Cancer, 2014, 2 (suppl. 3), O12 – Download the article Publication
Transgene Announces Third Quarter 2014 Financial Results
266_en
TIME: A Phase 2b/3 Evaluating TG4010 in Combination with First-line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC). Phase 2b results.
ESMO 2014-Poster TG4010 TIME Ph 2b Elisabeth Quoix, et al. ESMO 2014 Congress, Madrid, Spain, 26-30 September 2014, Abst. 5152 Download the poster here Poster Presentation
Transgene Reports Financial Results for First Six Months of 2014 and Provides Update on TG4010
261_en
Efficacy of immunotherapy with TG4040, Peg-interferon, and ribavirin in A phase 2 study of patients with chronic HCV infection.
Adrian Di Bisceglie, et al. Gastroenterology, 2014; Mar 18 – Download the article Publication
Comparative analysis of immunization schedules using a novel adenovirus – based immunotherapeutic targeting hepatitis B in naïve and tolerant mouse models.
Houda Boukhebza, et al. Vaccine. 2014, 32(26):3256-63. – Download the article Publication
Transgene Reports First Quarter 2014 Financial Results
254_en
Combination of the oncolytic vaccinia virus TG6002 with conventional chemotherapeutic agents in human tumor models resistant to viral oncolysis.
Johann Foloppe, et al. 8th International Conference on Oncolytic Virus Therapeutics. 10-13 April 2014, Oxford, United Kingdom, Abst. 64 Download the poster here Poster Presentation
Transgene Reports Fiscal Year 2013 Results and Provides Business Update
253_en
